Press releases

ORYZON reports results and corporate update for quarter ended March 31, 2022

ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

ORYZON to give updates on corporate progress in May

ORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and continues its expansion of US corporate activities

ORYZON to give updates on corporate progress in March and April

ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients

ORYZON to give updates on corporate progress in February and March

ORYZON reports results and corporate update for Q4 and year ended December 31, 2021

ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities

ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder